Illinois State University's Board of Trustees approved a COVID-19 testing contract with Reditus Laboratories.
The contract is to not exceed $3.3 million and will provide immediate support for surveillance testing for anyone not suffering from COVID-19 symptoms. The cost provides up to 30,000 tests being conducted with each test costing $110. About 1500 students will be tested each week throughout the fall semester.
Testing will be done at on-campus locations.
"As students return to campus, it is critical that university be able to conduct surveillance testing to protect the health and well-being of the campus community," said ISU President Larry Dietz.
The contract period will end Dec. 31.
ISU already holds a contract with Reditus Laboratories for symptomatic testing in which Student Health Services collects test samples for students exhibiting symptoms. The surveillance testing contract is a separate agreement.
Reditus Laboratories also conducted COVID-19 testing for university athletics earlier this summer to qualify athletes for participation in team practices and events. Reditus also works with Illinois Department of Public Health to manage the Interstate Center testing site located in Bloomington.